340 related articles for article (PubMed ID: 31537646)
1. Structure-based inhibitors halt prion-like seeding by Alzheimer's disease-and tauopathy-derived brain tissue samples.
Seidler PM; Boyer DR; Murray KA; Yang TP; Bentzel M; Sawaya MR; Rosenberg G; Cascio D; Williams CK; Newell KL; Ghetti B; DeTure MA; Dickson DW; Vinters HV; Eisenberg DS
J Biol Chem; 2019 Nov; 294(44):16451-16464. PubMed ID: 31537646
[TBL] [Abstract][Full Text] [Related]
2. Proteopathic tau seeding predicts tauopathy in vivo.
Holmes BB; Furman JL; Mahan TE; Yamasaki TR; Mirbaha H; Eades WC; Belaygorod L; Cairns NJ; Holtzman DM; Diamond MI
Proc Natl Acad Sci U S A; 2014 Oct; 111(41):E4376-85. PubMed ID: 25261551
[TBL] [Abstract][Full Text] [Related]
3. Tau exhibits unique seeding properties in globular glial tauopathy.
Chung DC; Carlomagno Y; Cook CN; Jansen-West K; Daughrity L; Lewis-Tuffin LJ; Castanedes-Casey M; DeTure M; Dickson DW; Petrucelli L
Acta Neuropathol Commun; 2019 Mar; 7(1):36. PubMed ID: 30845985
[TBL] [Abstract][Full Text] [Related]
4. Human tauopathy-derived tau strains determine the substrates recruited for templated amplification.
Tarutani A; Miyata H; Nonaka T; Hasegawa K; Yoshida M; Saito Y; Murayama S; Robinson AC; Mann DMA; Tomita T; Hasegawa M
Brain; 2021 Sep; 144(8):2333-2348. PubMed ID: 33693528
[TBL] [Abstract][Full Text] [Related]
5. Conformation determines the seeding potencies of native and recombinant Tau aggregates.
Falcon B; Cavallini A; Angers R; Glover S; Murray TK; Barnham L; Jackson S; O'Neill MJ; Isaacs AM; Hutton ML; Szekeres PG; Goedert M; Bose S
J Biol Chem; 2015 Jan; 290(2):1049-65. PubMed ID: 25406315
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of a conformational antibody that binds tau oligomers and inhibits pathological seeding by extracts from donors with Alzheimer's disease.
Abskharon R; Seidler PM; Sawaya MR; Cascio D; Yang TP; Philipp S; Williams CK; Newell KL; Ghetti B; DeTure MA; Dickson DW; Vinters HV; Felgner PL; Nakajima R; Glabe CG; Eisenberg DS
J Biol Chem; 2020 Jul; 295(31):10662-10676. PubMed ID: 32493775
[TBL] [Abstract][Full Text] [Related]
7. Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer's disease and other tauopathies.
Xia Y; Prokop S; Gorion KM; Kim JD; Sorrentino ZA; Bell BM; Manaois AN; Chakrabarty P; Davies P; Giasson BI
Acta Neuropathol Commun; 2020 Jun; 8(1):88. PubMed ID: 32571418
[TBL] [Abstract][Full Text] [Related]
8. Structure-based inhibitors of tau aggregation.
Seidler PM; Boyer DR; Rodriguez JA; Sawaya MR; Cascio D; Murray K; Gonen T; Eisenberg DS
Nat Chem; 2018 Feb; 10(2):170-176. PubMed ID: 29359764
[TBL] [Abstract][Full Text] [Related]
9. Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies.
Strang KH; Croft CL; Sorrentino ZA; Chakrabarty P; Golde TE; Giasson BI
J Biol Chem; 2018 Feb; 293(7):2408-2421. PubMed ID: 29259137
[TBL] [Abstract][Full Text] [Related]
10. Heterotypic seeding of Tau fibrillization by pre-aggregated Abeta provides potent seeds for prion-like seeding and propagation of Tau-pathology in vivo.
Vasconcelos B; Stancu IC; Buist A; Bird M; Wang P; Vanoosthuyse A; Van Kolen K; Verheyen A; Kienlen-Campard P; Octave JN; Baatsen P; Moechars D; Dewachter I
Acta Neuropathol; 2016 Apr; 131(4):549-69. PubMed ID: 26739002
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design of nanobodies that inhibit seeding of Alzheimer's patient-extracted tau fibrils.
Abskharon R; Pan H; Sawaya MR; Seidler PM; Olivares EJ; Chen Y; Murray KA; Zhang J; Lantz C; Bentzel M; Boyer DR; Cascio D; Nguyen BA; Hou K; Cheng X; Pardon E; Williams CK; Nana AL; Vinters HV; Spina S; Grinberg LT; Seeley WW; Steyaert J; Glabe CG; Ogorzalek Loo RR; Loo JA; Eisenberg DS
Proc Natl Acad Sci U S A; 2023 Oct; 120(41):e2300258120. PubMed ID: 37801475
[TBL] [Abstract][Full Text] [Related]
12. Fungally Derived Isoquinoline Demonstrates Inducer-Specific Tau Aggregation Inhibition.
Ingham DJ; Blankenfeld BR; Chacko S; Perera C; Oakley BR; Gamblin TC
Biochemistry; 2021 Jun; 60(21):1658-1669. PubMed ID: 34009955
[TBL] [Abstract][Full Text] [Related]
13. Highly Specific and Sensitive Target Binding by the Humanized pS396-Tau Antibody hC10.2 Across a Wide Spectrum of Alzheimer's Disease and Primary Tauopathy Postmortem Brains.
Helboe L; Rosenqvist N; Volbracht C; Pedersen LØ; Pedersen JT; Christensen S; Egebjerg J; Christoffersen CT; Bang-Andersen B; Beach TG; Serrano GE; Falsig J
J Alzheimers Dis; 2022; 88(1):207-228. PubMed ID: 35570492
[TBL] [Abstract][Full Text] [Related]
14. Tau R2 and R3 are essential regions for tau aggregation, seeding and propagation.
Annadurai N; Malina L; Malohlava J; Hajdúch M; Das V
Biochimie; 2022 Sep; 200():79-86. PubMed ID: 35623497
[TBL] [Abstract][Full Text] [Related]
15. Trans-seeding of Alzheimer-related tau protein by a yeast prion.
Flach M; Leu C; Martinisi A; Skachokova Z; Frank S; Tolnay M; Stahlberg H; Winkler DT
Alzheimers Dement; 2022 Dec; 18(12):2481-2492. PubMed ID: 35142027
[TBL] [Abstract][Full Text] [Related]
16. Towards a Mechanistic Model of Tau-Mediated Pathology in Tauopathies: What Can We Learn from Cell-Based In Vitro Assays?
Sala-Jarque J; Zimkowska K; Ávila J; Ferrer I; Del Río JA
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232835
[TBL] [Abstract][Full Text] [Related]
17. Amyloidogenesis of Tau protein.
Nizynski B; Dzwolak W; Nieznanski K
Protein Sci; 2017 Nov; 26(11):2126-2150. PubMed ID: 28833749
[TBL] [Abstract][Full Text] [Related]
18. Characterization of tau prion seeding activity and strains from formaldehyde-fixed tissue.
Kaufman SK; Thomas TL; Del Tredici K; Braak H; Diamond MI
Acta Neuropathol Commun; 2017 Jun; 5(1):41. PubMed ID: 28587664
[TBL] [Abstract][Full Text] [Related]
19. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody.
Albert M; Mairet-Coello G; Danis C; Lieger S; Caillierez R; Carrier S; Skrobala E; Landrieu I; Michel A; Schmitt M; Citron M; Downey P; Courade JP; Buée L; Colin M
Brain; 2019 Jun; 142(6):1736-1750. PubMed ID: 31038156
[TBL] [Abstract][Full Text] [Related]
20. GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils.
Gibbons GS; Banks RA; Kim B; Xu H; Changolkar L; Leight SN; Riddle DM; Li C; Gathagan RJ; Brown HJ; Zhang B; Trojanowski JQ; Lee VM
J Neurosci; 2017 Nov; 37(47):11485-11494. PubMed ID: 28986461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
